Filtered By:
Condition: Thrombosis
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 230 results found since Jan 2013.

A Special Clinical Scenario for Transcatheter Aortic Valve Replacement: "Iatrogenic Double-Outlet" Left Ventricle
This report offers some guidance for treating patients with existing apicoaortic conduits and suggests that transcatheter aortic valve replacement is safe and effective if native aortic valve insufficiency develops.PMID:36174575 | DOI:10.14503/THIJ-22-7889
Source: Texas Heart Institute Journal - September 29, 2022 Category: Cardiology Authors: Alexander Postalian Sudeep Kuchibhotla Srikanth Koneru Neil E Strickman Source Type: research

Perioperative and long ‐term outcomes of Ross versus mechanical aortic valve replacement
ConclusionsIn this mid-term propensity score-matched analysis, the Ross procedure offers similar perioperative outcomes, freedom from reintervention or valve dysfunction as well as overall survival compared to traditional mAVR but without the morbidity associated with long-term anticoagulation. At specialized centers with sufficient expertize, the Ross procedure should be strongly considered in select patients requiring aortic valve replacement.
Source: Journal of Cardiac Surgery - August 22, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Chelsea D. Wenos, Jeremy L. Herrmann, Lava R. Timsina, Parth M. Patel, John W. Fehrenbacher, John W. Brown Tags: ORIGINAL ARTICLE Source Type: research

Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients 　- A Subanalysis of the ENVISAGE-TAVI AF Trial
CONCLUSIONS: In Japanese patients with AF after successful TAVR, edoxaban and VKA treatment have similar safety and efficacy profiles.PMID:35965066 | DOI:10.1253/circj.CJ-22-0093
Source: Circulation Journal - August 14, 2022 Category: Cardiology Authors: Yusuke Watanabe Kentaro Hayashida Masanori Yamamoto Futoshi Yamanaka Kazumasa Yamasaki Toru Naganuma Yohei Ohno Masahiro Yamawaki Nobuyuki Morioka Kazuki Mizutani Norio Tada Hiroshi Ueno Hidetaka Nishina Masaki Izumo Yoshifumi Nakajima Kenji Ando Kensuke Source Type: research

E-223 Atypical delayed mechanical thrombectomy for calcified cardiac emboli
ConclusionMechanical thrombectomy for intermittent stroke symptoms due to CCE was successfully achieved using an Embotrap device despite several days of relapsing-remitting symptoms with full neurologic recovery. Regardless of prior reports showing a low success rate, with the advent and availability of advanced thrombectomy devices, tailored endovascular treatment for patients with CCE to the brain should be strongly considered.Disclosures A. Pandhi: None. A. Alrohimi: None. A. Mahapatra: None. A. Russman: None. G. Toth: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Pandhi, A., Alrohimi, A., Mahapatra, A., Russman, A., Toth, G. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

One ‐year outcome after transcatheter aortic valve replacement for aortic regurgitation: A single‐center study
ConclusionsIn high-risk patients undergoing transapical TAVR for AR, the use of the J-Valve is safe, and effective TAVR should be considered as a reasonable option for high-risk patients with pure AR.
Source: Journal of Cardiac Surgery - January 19, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Lulu Liu, Xiaoling Yao, Ying Peng, Weina Huang, Shi Jun, Hong Qian, Yilong Chen, Yingqiang Guo Tags: ORIGINAL ARTICLE Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Impact of mitral versus aortic bioprosthetic valve position  on thromboembolism and bleeding risk in patients with atrial fibrillation
CONCLUSIONS: In Japanese patients with AF and bioprosthetic valves, thromboembolic risk does not differ on the basis of valve position. Bleeding risk is higher in patients with MV bioprostheses, although valve position itself might not be an independent predictor for bleeding.PMID:34716054 | DOI:10.1016/j.jjcc.2021.10.002
Source: Journal of Cardiology - October 30, 2021 Category: Cardiology Authors: Yuki Obayashi Makoto Miyake Masashi Amano Takeshi Kitai Misa Takegami Kunihiro Nishimura Toshihiro Tamura Yutaka Furukawa Chisato Izumi Source Type: research